NCT02662712View on ClinicalTrials.gov

A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions
HealthyHepatitis, Chronic
Interventions
DRUG

JNJ-56136379

JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

DRUG

Placebo

Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

Trial Locations (27)

Unknown

Brussels

Edegem

Mechelen

Merksem

Sofia

Clichy

La Tronche

Lyon

Paris

Tbilisi

Essen

Hanover

Wiesbaden

Kuala Lumpur

Chisinau

Bucharest

Timișoara

Barcelona

Madrid

Santander

Seville

Valencia

Kaohsiung City

Keelung

Taichung

Taipei

Taoyuan District

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT02662712 - A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) | Biotech Hunter | Biotech Hunter